Insider Cluster (2 insiders) ·Filed Jul 6, 2026

PCVX

Vaxcyte, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed2mo ago
Insider cluster: 2 insiders, $478K total
Actionable Insight • Neutral

The cluster is too small to signal a change in fundamentals. Monitor for any >$8M insider sales (0.1% of market cap) that would be material. The prior 30-day insider activity of $1.1M in total sales also remains below the threshold.

DirectionNeutral
Confidencehigh
Horizonimmediate
Final — all horizons settled through T+60d ⚠ clustered
PCVX ▼ -6.21% at T+60d
NEUTRAL call ✗ call lost -6.21% · α vs SPY -8.21% · entry $60.67 → $56.90
Entry anchored
Jul 6, 03:59 PM ET
via exchange tick
T+1d
-3.23%
call -3.23% · α -2.92%
$58.71
settled 3mo ago
T+5d
-7.35%
call -7.35% · α -7.90%
$56.21
settled 3mo ago
T+20d
-11.77%
call -11.77% · α -13.10%
$53.53
settled 2mo ago
T+60d
-6.21%
call -6.21% · α -8.21%
$56.90
settled 3d ago

Price Chart

Loading chart...

Executive Summary

Two C-suite insiders at Vaxcyte (PCVX) sold shares worth $478K in the past week, but the amount is negligible relative to the $8.4B market cap (0.006%). The trades are routine option exercises and small share sales, not indicative of a bearish view.

Key Financial Metrics

Direction
selling
Total Value
$478.0K
Insiders
2

Key Facts

  • President and CFO Andrew Guggenhime sold 7,900 shares for $452K on July 6, 2026.
  • COO Jim Wassil sold 456 shares for $26K on July 1, 2026.
  • Total open-market sales of $478K represent ~0.006% of market cap — well below the 0.1% materiality threshold.
  • Both transactions followed derivative exercises (non-cash events), typical for tax withholding and profit-taking.

Financial Impact

Insider sales of $478K are trivial relative to $8.4B market cap.

insider_ownershipdilution

Risk Factors

  • Insider selling could accelerate if the stock continues to rise, but the current magnitude is routine.
  • No other recent filings (e.g., earnings, restatements) to contextualize the sales — treat as standalone liquidity events.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
88% bullish (17 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-PCVX-1783382471838
13 reports for PCVX
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for PCVX — sortable, filterable
TypeNow
Aug 5, 2026
8w ago
Insider Cluster
NEUTRAL ★ 2/10
$55.92 $61.58▲ +10.12%▲ +10.72%$56.69 (+1.38%)
Jul 6, 2026
12w ago
Insider Cluster
NEUTRAL ★ 2/10
$60.67 $53.53▼ −11.77%▼ −13.10%$56.69 (−6.56%)
Jul 6, 2026
12w ago
Insider Cluster
NEUTRAL ★ 2/10
$60.67 $53.53▼ −11.77%▼ −13.10%$56.69 (−6.56%)
Jun 26, 2026
13w ago
144
NEUTRAL ★ 3/10
$57.72 $54.66▼ −5.30%▼ −5.02%$56.69 (−1.78%)
Jun 23, 2026
14w ago
8-K
NEUTRAL ★ 2/10
$53.87 $56.00▲ +3.95%▲ +2.02%$56.69 (+5.23%)
Jun 19, 2026
15w ago
Insider Cluster
NEUTRAL ★ 3/10
$52.11 $56.20▲ +7.85%▲ +8.00%$56.69 (+8.79%)
Jun 2, 2026
17w ago
Press Release
NEUTRAL ★ 4/10
$46.93 $58.39▲ +24.42%▲ +25.42%$56.69 (+20.80%)
May 6, 2026
21w ago
8-K
BEARISH ★ 7/10
$51.48 $46.93▲ +8.84%▲ +11.97%$56.69 (−10.12%)
Apr 23, 2026
23w ago
DEFA14A
NEUTRAL ★ 3/10
$59.49 $47.39▼ −20.34%▼ −24.37%$56.69 (−4.71%)
Apr 1, 2026
26w ago
Insider Cluster
NEUTRAL ★ 3/10
$58.50 $57.32▼ −2.02%▼ −11.74%$56.69 (−3.09%)
Showing 10 of 13

US Market Status

Market Open — Closes in 3h 56m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Jul 7, 2026